

Research article

Open Access

Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivorsMarilyn L Kwan¹, Lawrence H Kushi¹, Erin Weltzien¹, Benjamin Maring¹, Susan E Kutner², Regan S Fulton³, Marion M Lee⁴, Christine B Ambrosone⁵ and Bette J Caan¹¹Kaiser Permanente, Division of Research, 2000 Broadway, First Floor, Oakland, CA 94612, USA²Kaiser Permanente, San Jose, 280 Hospital Parkway, San Jose, CA 95119, USA³Kaiser Permanente, Regional Immunohistochemistry Laboratory, 350 St. Joseph's Street, San Francisco, CA 94115, USA⁴Department of Epidemiology and Biostatistics, Box 0981, 185 Berry Street 6600, University of California, San Francisco, CA 94143-0981, USA⁵Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USACorresponding author: Marilyn L Kwan, marilyn.l.kwan@kp.org

Received: 6 Jan 2009 Revisions requested: 23 Feb 2009 Revisions received: 23 Mar 2009 Accepted: 22 May 2009 Published: 22 May 2009

Breast Cancer Research 2009, **11**:R31 (doi:10.1186/bcr2261)This article is online at: <http://breast-cancer-research.com/content/11/3/R31>© 2009 Kwan *et al.*; licensee BioMed Central Ltd.This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.**Abstract**

Introduction The aim of this study was to describe breast tumor subtypes by common breast cancer risk factors and to determine correlates of subtypes using baseline data from two pooled prospective breast cancer studies within a large health maintenance organization.

Methods Tumor data on 2544 invasive breast cancer cases subtyped by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (Her2) status were obtained (1868 luminal A tumors, 294 luminal B tumors, 288 triple-negative tumors and 94 Her2-overexpressing tumors). Demographic, reproductive and lifestyle information was collected either in person or by mailed questionnaires. Case-only odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression, adjusting for age at diagnosis, race/ethnicity, and study origin.

Results Compared with luminal A cases, luminal B cases were more likely to be younger at diagnosis ($P = 0.0001$) and were less likely to consume alcohol (OR = 0.74, 95% CI = 0.56 to 0.98), use hormone replacement therapy (HRT) (OR = 0.66, 95% CI = 0.46 to 0.94), and oral contraceptives (OR = 0.73,

95% CI = 0.55 to 0.96). Compared with luminal A cases, triple-negative cases tended to be younger at diagnosis ($P \leq 0.0001$) and African American (OR = 3.14, 95% CI = 2.12 to 4.16), were more likely to have not breastfed if they had parity greater than or equal to three (OR = 1.68, 95% CI = 1.00 to 2.81), and were more likely to be overweight (OR = 1.82, 95% CI = 1.03 to 3.24) or obese (OR = 1.97, 95% CI = 1.03 to 3.77) if premenopausal. Her2-overexpressing cases were more likely to be younger at diagnosis ($P = 0.03$) and Hispanic (OR = 2.19, 95% CI = 1.16 to 4.13) or Asian (OR = 2.02, 95% CI = 1.05 to 3.88), and less likely to use HRT (OR = 0.45, 95% CI = 0.26 to 0.79).

Conclusions These observations suggest that investigators should consider tumor heterogeneity in associations with traditional breast cancer risk factors. Important modifiable lifestyle factors that may be related to the development of a specific tumor subtype, but not all subtypes, include obesity, breastfeeding, and alcohol consumption. Future work that will further categorize triple-negative cases into basal and non-basal tumors may help to elucidate these associations further.

Introduction

Among women in the USA, breast cancer remains the most commonly diagnosed cancer, excluding skin cancers, and the second leading cause of cancer-related death [1]. Breast can-

cer is characterized by its molecular and clinical heterogeneity. Studies using cDNA microarrays and immunohistochemical (IHC) markers [2-6] have classified breast cancers into five distinct subtypes: luminal A (estrogen receptor (ER) positive

BMI: body mass index; CBCS: Carolina Breast Cancer Study; CI: confidence interval; CK: cytokeratin; EGFR: epidermal growth factor receptor; ER: estrogen receptor; FISH: fluorescence *in situ* hybridization; Her2: human epidermal growth factor receptor 2; HRT: hormone replacement therapy; IHC: immunohistochemical; IRB: institutional review board; KPNC: Kaiser Permanente Northern California; LACE: Life After Cancer Epidemiology; OC: oral contraceptive; OR: odds ratio; PBCS: Polish Breast Cancer Study; PR: progesterone receptor; WS: Washington State.

and/or progesterone receptor (PR) positive, human epidermal growth factor receptor 2 (Her2) negative), luminal B (ER positive and/or PR positive, Her2 positive), Her2 overexpressing (ER negative, PR negative, Her2 positive), basal-like (ER negative, PR negative, Her2 negative, cytokeratin (CK) 5/6 positive and/or epidermal growth factor receptor (EGFR) positive) and normal breast-like tumors. Approximately 70% of 'triple-negative' breast cancers (ER negative, PR negative, Her2 negative) express basal markers [7-9], resulting in the triple-negative subtype commonly being used as a surrogate marker for the basal-like subtype.

Luminal tumors have been associated with the most favorable prognoses, while Her2-overexpressing and basal-like tumors, or their surrogate triple negative tumors, have been associated with the worst prognoses [2,3,5,6,10-18]. For triple-negative tumors, the peak risk of recurrence occurs within three years of diagnosis, and mortality rates are increased for five years after diagnosis [14,19]. The subtype accounts for approximately 15% of invasive breast cancers [2,4,10,11,20] and is commonly associated with African American race [2,10,17,20-22], younger age at diagnosis [10,11,14,16,17,19,20,22-24], more advanced stage [10,11,24], higher grade [2,5,9,11,14,16,17,19,21,24,25], high mitotic indices [2,16,26], family history of breast cancer [27], and BRCA1 mutations [23,28,29].

Although many studies have examined associations between common breast cancer risk factors, race [30-36] and hormone receptor status [36-41], few studies have explored the relationship between common breast cancer risk factors and the molecular subtypes of breast cancer [22,27,42,43] [see Additional data file 1]. Therefore, we set out to describe breast tumor subtypes by race/ethnicity and common breast cancer risk factors and to determine correlates of breast cancer subtypes using baseline data from two large, prospective breast cancer survivorship studies of 2544 invasive breast cancer cases.

Materials and methods

LACE Study

The Life After Cancer Epidemiology (LACE) Study consists of 2280 women diagnosed with invasive breast cancer between 1997 and 2000 and recruited primarily from the Kaiser Permanente Northern California (KPNC) Cancer Registry (82%) and the Utah Cancer Registry (12%). Further details on the LACE cohort have been previously reported [44]. Briefly, eligibility criteria included age between 18 and 70 years at enrollment; a diagnosis of early-stage primary breast cancer (stages I \geq 1 cm, II, or IIIA); enrollment between 11 and 39 months post-diagnosis; having completed breast cancer treatment (except for adjuvant hormonal therapy); free of recurrence; and no history of other cancers in the five years prior to enrollment. Between January 2000 and April 2002, 2280 eligible women completed baseline questionnaires via mail. The mean time

from diagnosis to enrollment was 22.8 months (range = 11.0 to 38.9 months). The study was approved by the institutional review boards (IRB) of KPNC and the University of Utah. The present analysis includes data from 1821 KPNC breast cancer patients from the LACE Study with complete breast cancer subtype information.

Pathways Study

The Pathways Study is a prospective cohort study actively recruiting women diagnosed with invasive breast cancer from the KPNC patient population since January 2006. Women are recruited as soon after diagnosis as possible (usually within two months), as described elsewhere [45]. Briefly, cases are rapidly ascertained on a daily basis by automatic scanning of electronic pathology reports with subsequent verification of cancer diagnosis and patient notification by a medical record analyst. Eligibility criteria include: current KPNC membership; at least 21 years of age at diagnosis; recent diagnosis of first primary invasive breast cancer (all stages); no prior history of any cancer; ability to speak English, Spanish, Cantonese, or Mandarin; and live within a 65-mile radius of a field interviewer. In addition, a passive consent is obtained from the patient's physician of record by an email notification stating our intention to contact the patient for study recruitment. Recruitment is ongoing, and as of 20 October, 2008, 2212 breast cancer patients have been enrolled via in-person interview. The mean time from diagnosis to enrollment is 1.9 months (range = 0 to 7.3 months). Written informed consent is obtained from all participants before they are enrolled in the study, typically at the time of the in-person baseline interview. The study was approved by the IRB of KPNC and all collaborating sites. In order to make these cases comparable with those from the LACE Study, the present analysis includes data from the first 723 women enrolled with a diagnosis of stages I \geq 1 cm, II, or IIIA breast cancer and having complete breast cancer subtype data.

Data collection

Reproductive and lifestyle factors

In the mailed baseline questionnaire of the LACE Study and during the in-person baseline interview of the Pathways Study, participants were asked detailed information on family history of cancer and reproductive history, including age at first full-term pregnancy, number of biological children, breastfeeding, and menopausal status. Additional information was collected on smoking, alcohol use, hormone use (oral contraceptives (OC), hormone replacement therapy (HRT)), and demographics (age at breast cancer diagnosis, race/ethnicity, household income, education). Self-reported height and weight one year before diagnosis (LACE) and around diagnosis (Pathways) was obtained to calculate body mass index (BMI, kg/m²). Any missing values were supplemented by concurrent information from KPNC electronic medical records.

Table 1**Distribution of demographic, reproductive, and lifestyle risk factors by race/ethnicity in the combined LACE and Pathways Studies (n = 2544)**

	White Total n = 1943 n (%)	African American Total n = 155 n (%)	Asian Total n = 189 n (%)	Hispanic Total n = 197 n (%)	Other Total n = 54 n (%)	P value ^a
Age at diagnosis (years)						< 0.0001
< 50	389 (20.0)	43 (27.7)	61 (32.3)	67 (34.0)	13 (24.1)	
50 to 64	879 (45.2)	80 (51.6)	87 (46.0)	80 (40.6)	29 (53.7)	
≥ 65	675 (34.7)	32 (20.6)	41 (21.7)	50 (25.4)	12 (22.2)	
mean (± standard deviation)	59.8 (11.2)	56.2 (10.7)	54.8 (11.0)	55.7 (12.4)	57.7 (9.8)	
Menopausal status						< 0.0001
Postmenopausal	1,330 (75.6)	90 (71.4)	104 (59.1)	117 (65.4)	35 (72.9)	
Premenopausal	430 (24.4)	36 (28.6)	72 (40.9)	62 (34.6)	13 (27.1)	
Family history						0.001
No	1,503 (77.4)	133 (85.8)	163 (86.2)	167 (84.8)	41 (75.9)	
Yes	440 (22.6)	22 (14.2)	26 (13.8)	30 (15.2)	13 (24.1)	
Parity						0.006
Nulliparous	343 (17.7)	22 (14.2)	46 (24.3)	31 (15.7)	9 (16.7)	
1 to 2 children	894 (46.0)	67 (43.2)	93 (49.2)	79 (40.1)	31 (57.4)	
≥ 3 children	706 (36.3)	66 (42.6)	50 (26.5)	87 (44.2)	14 (25.9)	
Age at first full-term pregnancy (years)						< 0.0001
Nulliparous	343 (17.7)	22 (14.3)	46 (24.3)	31 (15.8)	9 (16.7)	
< 26	1,020 (52.6)	113 (73.4)	61 (32.3)	119 (60.7)	28 (51.9)	
≥ 26	578 (29.8)	19 (12.3)	82 (43.4)	46 (23.5)	17 (31.5)	
Lifetime duration of lactation						0.215
Never	908 (47.3)	92 (59.7)	81 (44.3)	91 (48.1)	25 (47.2)	
0 to 3 months	279 (14.5)	19 (12.3)	31 (16.9)	25 (13.2)	8 (15.1)	
≥ 4 months	733 (38.2)	43 (27.9)	71 (38.8)	73 (38.6)	20 (37.7)	
Alcohol use						< 0.0001
Never	675 (39.9)	77 (67.5)	116 (75.3)	93 (62.4)	28 (57.1)	
Ever	1,016 (60.1)	37 (32.5)	38 (24.7)	56 (37.6)	21 (42.9)	
Smoking history (years)						< 0.0001
Never	925 (48.0)	73 (47.4)	148 (78.3)	113 (57.4)	22 (40.7)	
≤ 10	269 (14.0)	17 (11.0)	13 (6.9)	33 (16.8)	6 (11.1)	
11 to 19	169 (8.8)	10 (6.5)	8 (4.2)	6 (3.0)	5 (9.3)	
≥ 20	563 (29.2)	54 (35.1)	20 (10.6)	45 (22.8)	21 (38.9)	
Hormone replacement therapy (postmenopausal women only)						
Never	310 (23.8)	37 (42.1)	47 (45.6)	37 (32.2)	12 (34.3)	
Ever	994 (76.2)	51 (57.9)	56 (54.4)	78 (67.8)	23 (65.7)	
Oral contraceptive use						< 0.0001

Table 1 (Continued)**Distribution of demographic, reproductive, and lifestyle risk factors by race/ethnicity in the combined LACE and Pathways Studies (n = 2544)**

Never	638 (33.8)	40 (26.7)	100 (55.9)	72 (37.7)	16 (30.2)
Ever	1,252 (66.2)	110 (73.3)	79 (44.1)	119 (62.3)	37 (69.8)
Body mass index (kg/m ²) ^b					< 0.0001
< 25	835 (43.4)	31 (20.0)	119 (63.3)	63 (32.5)	20 (37.0)
25 to 29	600 (31.1)	48 (31.0)	46 (24.5)	64 (33.0)	14 (25.9)
≥ 30	491 (25.5)	76 (49.0)	23 (12.2)	67 (34.5)	20 (37.0)

^aFrom Pearson chi-square test across racial/ethnic categories.

^bBody mass index one year pre-diagnosis (LACE) and around diagnosis (Pathways).

Tumor characteristics

Data on ER and PR status and Her2 expression were obtained from medical record review and the KPNC Cancer Registry [46] for LACE and from the KPNC Cancer Registry and other KPNC databases for Pathways. Data are collected, coded, and added to the KPNC Cancer Registry approximately four months after diagnosis to allow for the completion of treatment. For all breast surgical specimens, hormone receptor status, and Her2 expression is determined by IHC at the KPNC regional IHC laboratory and has been reported to the KPNC Cancer Registry since January 2000. Gene expression profiling studies have shown that IHC of paraffin sections is a reliable surrogate for molecular classification of invasive breast cancers [3,47-51]. Beginning in July 1999, if the IHC staining for Her2 expression is equivocal (less than 30% strong staining, but more than 10% weak staining), then the specimen is sent for fluorescence *in situ* hybridization (FISH) at the KPNC regional cytogenetics laboratory. If the FISH score (Her2: 17 cen) is less than 2.0 [52], then the woman is classified as having Her2-negative tumor expression; if the FISH score is greater than 2.0, then the woman is classified as having Her2-positive tumor expression. Results from FISH analyses are not reported to the KPNC Cancer Registry, and are obtained directly from the KPNC regional cytogenetics laboratory.

Covariate classification

Demographic, reproductive, and lifestyle covariates of interest were classified as follows: age at diagnosis (< 50, 50 to 64, ≥ 65 years), race/ethnicity (white, African American, Hispanic, Asian, other), menopausal status (pre, post), family history of breast cancer (no, yes), parity (nulliparous, 1 to 2, ≥ 3 children), age at first full-term pregnancy (nulliparous, < 26, ≥ 26 years), lifetime duration of lactation (never, 0 to 3, ≥ 4 months), alcohol use (never, ever), smoking duration (never, ≤ 10, 11 to 19, ≥ 20 years), hormone replacement therapy (HRT) among post-menopausal women (never, ever), OC use (never, ever), and BMI (< 25, 25 to 29, ≥ 30 kg/m²).

Outcome classification

Although the presence of basal markers can significantly improve the prognostic value of the triple-negative phenotype

[13], for this analysis, we did not have IHC data for CK5/6 and EGFR expression. Thus, we were unable to further classify triple-negative cases into basal-like and non-basal-like breast tumors. Considering this limitation, the tumor subtype groups in this analysis consisted of: ER positive and/or PR positive, and Her2 negative (luminal A); ER positive and/or PR positive, and Her2 positive (luminal B); ER negative, PR negative, and Her2 negative (triple negative); ER negative, PR negative, and Her2 positive (Her2-overexpressing).

Statistical analysis

Comparisons of demographic, reproductive, and lifestyle characteristics by cohort study and race/ethnicity were conducted using Pearson chi-square tests. Using the combined sample size of 2544 breast cancer survivors, case-only odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression. The luminal A group was selected as the referent because the majority of invasive breast cancer cases are of this subtype. All models were adjusted for age at diagnosis, race/ethnicity, and Pathways/LACE study origin except when these covariates were the predictors of interest. We also examined whether the associations between parity and tumor subtype varied by breastfeeding and whether BMI and tumor subtype varied by menopausal status by first generating strata-specific estimates and then including an interaction term in the model to test for statistical significance. CIs not overlapping with 1.00 or $P < 0.05$ were considered statistically significant.

Results

Demographic, reproductive, and lifestyle factors varied significantly by race/ethnicity in the combined studies (Table 1). Demographically, African Americans (mean age = 56.2 years) and Asians (mean age = 54.8 years) were more likely to be diagnosed at a younger age although whites were more likely to be diagnosed at an older age (mean age = 59.8 years). However, Asians (59.1%) were less likely to be post-menopausal than whites (75.6%), African Americans (71.4%), and other races/ethnicities (72.9%). A positive family history of breast cancer was more common among whites (22.6%) and other races/ethnicities (24.1%), than among the other groups.

Reproductive history also differed markedly by race/ethnicity; African Americans and Hispanics had more biological children (42.6% and 44.2%, respectively) and were younger during their first pregnancy (73.4% and 60.7%) compared with the other races/ethnicities. Whites were more likely to have ever consumed alcohol (60.1%) while Asians (78.3%) were more likely to have never smoked. Among the hormonal factors, more whites had used HRT (76.2%) compared with the other races/ethnicities, while fewer Asians (44.1%) had used OCs compared with the other races/ethnicities. African Americans were more obese at diagnosis (49.0%) followed by other races/ethnicities (37.0%) and Hispanics (34.5%). Additional data file 2 shows the distribution of demographic, reproductive, and lifestyle factors in the LACE and Pathways Studies separately. Overall, the two study populations were similar demographically, yet non-similarities were apparent among reproductive and hormonal factors, likely to be due to differences in time periods of data collection.

The distribution of breast cancer subtypes by race/ethnicity in the combined studies is presented in Table 2. Among the 2544 invasive breast cancer cases, 1868 (73.4%) were classified as luminal A, 294 (11.6%) as luminal B, 288 (11.3%) as triple negative, and 94 (3.7%) as Her2-overexpressing. The distribution of race/ethnicity within each subtype compared with all other subtypes varied significantly ($P < 0.05$). The majority of the whites (75.3%), Asians (71.4%), Hispanics (68.5%), other (68.5%), and African Americans (59.4%) had the luminal A tumor subtype. The Her2-overexpressing subtype was least common among all races/ethnicities (whites 3.1%, African Americans 3.2%, Asians 6.4%, Hispanics 6.6%, other 5.5%). African Americans had the highest prevalence of the triple negative subtype (28.4%) compared with the other races/ethnicities (whites 10.5%, Asians 6.3%, Hispanics 10.7%, other 13.0%).

The associations between various demographic, reproductive, and lifestyle factors within each subtype (luminal B, triple negative, and Her2-overexpressing) compared with luminal A are shown in Tables 3 and 4. All case-only ORs were adjusted for age, race/ethnicity, and Pathways/LACE study origin except when either age at diagnosis or race/ethnicity were the main predictors in the logistic regression model. Compared with luminal A cases, luminal B cases were more likely to be younger at diagnosis (OR for < 50 years = 1.83, 95% CI = 1.32 to 2.55; $P = 0.0001$) and were less likely to consume alcohol (OR = 0.74, 95% CI = 0.56 to 0.98), use HRT (OR = 0.66, 95% CI = 0.46 to 0.94), and OC (OR = 0.73, 95% CI = 0.55 to 0.96). Compared with luminal A cases, triple negative cases tended to be younger at diagnosis (OR for < 50 years = 2.78, 95% CI = 1.99 to 3.90; $P \leq 0.0001$) and African American (OR = 3.14, 95% CI = 2.12 to 4.16). Breastfeeding for at least four months was associated with being less likely to have a triple negative tumor, yet this association was of borderline significance (OR = 0.78, 95% CI = 0.59 to 1.03). Compared with luminal A cases, Her2-overexpressing cases were more likely to be younger at diagnosis ($P = 0.03$), similar to luminal B and triple negative cases, and less likely to use HRT (OR = 0.49, 95% CI = 0.26 to 0.79), similar to luminal B cases. Furthermore, Her2-overexpressing cases were more likely to be Hispanic (OR = 2.19, 95% CI = 1.16 to 4.13) and Asian (OR = 2.02, 95% CI = 1.05 to 3.88). The associations between the risk factors and tumor subtypes for the individual studies are presented in Additional data files 3 and 4. The majority of the case-only ORs were in the same direction as observed in the combined analysis, except for the association between BMI and the triple-negative subtype. In the LACE Study, triple-negative cases were more likely to have higher

Table 2**Distribution of breast cancer tumor subtypes by race/ethnicity in the combined LACE and Pathways Studies (n = 2544)**

Tumor subtype	White n (%)	African American n (%)	Asian n (%)	Hispanic n (%)	Other n (%)	P value ^a
Luminal A (ER+ and/or PR+, Her2-) n = 1868 (73.4)	1464 (75.3)	92 (59.4)	135 (71.4)	135 (68.5)	37 (68.5)	0.0001
Luminal B (ER+ and/or PR+, Her2+) n = 294 (11.6)	215 (11.1)	14 (9.0)	30 (15.9)	28 (14.2)	7 (13.0)	0.18
Triple negative (ER-, PR-, Her2-) n = 288 (11.3)	204 (10.5)	44 (28.4)	12 (6.3)	21 (10.7)	7 (13.0)	< 0.0001
Her2 overexpressing (ER-, PR-, Her2+) n = 94 (3.7)	60 (3.1)	5 (3.2)	12 (6.4)	13 (6.6)	3 (5.5)	0.03
Total n = 2544 (100)	1943 (100)	155 (100)	189 (100)	197 (100)	54 (100)	---

^a From Pearson chi-square test across racial/ethnic categories.

ER = estrogen receptor; Her2 = human epidermal growth receptor 2; PR = progesterone receptor; + = positive; - = negative.

Table 3

Case-only odds ratios and 95% confidence intervals from logistic regression models^a of associations between breast cancer tumor subtypes and demographic, reproductive, and lifestyle risk factors, combined LACE and Pathways Studies (n = 2544)

	Luminal A (comparison)		Luminal B ^a	
	n	N	OR	95% CI
Age at diagnosis (years)				
≥ 65 (Ref)	637	82	Ref	---
50 to 64	871	124	1.09	0.81, 1.47
< 50	355	88	1.83	1.32, 2.55
Test for trend				<i>P</i> = 0.0001
Race/ethnicity				
White (Ref)	1464	215	Ref	---
African American	92	14	0.97	0.54, 1.74
Hispanic	135	28	1.32	0.85, 2.04
Asian	135	30	1.38	0.90, 2.12
Other	37	7	1.29	0.56, 2.94
Menopausal status				
Postmenopausal (Ref)	1283	173	Ref	---
Premenopausal	406	95	1.32	0.87, 2.00
Family history				
No (Ref)	1453	245	Ref	---
Yes	410	49	0.74	0.53, 1.02
Age at first full-term pregnancy (years)				
Nulliparous (Ref)	335	51	Ref	---
< 26	959	158	1.25	0.88, 1.78
≥ 26	567	85	1.04	0.72, 1.52
Parity				
Nulliparous (Ref)	335	51	Ref	---
1 to 2 children	837	150	1.24	0.88, 1.76
≥ 3 children	691	93	1.03	0.70, 1.50
Lifetime duration of breastfeeding				
Never (Ref)	871	135	Ref	---
0 to 3 months	255	50	1.31	0.92, 1.88
≥ 4 months	711	100	0.86	0.65, 1.14
Parity among never breastfed ^b				
Nulliparous (Ref)	321	50	Ref	---
1 to 2 children	326	59	1.38	(0.89, 2.13)
≥ 3 children	224	26	1.01	(0.58, 1.76)
Parity among 0 to 3 months breastfed ^b				
1 to 2 children (Ref)	144	33	Ref	---
≥ 3 children	108	17	0.90	(0.45, 1.77)
Parity among ≥ 4 months breastfed ^b				

Table 3 (Continued)**Case-only odds ratios and 95% confidence intervals from logistic regression models^a of associations between breast cancer tumor subtypes and demographic, reproductive, and lifestyle risk factors, combined LACE and Pathways Studies (n = 2544)**

1 to 2 children (Ref)	358	56	Ref	---
≥ 3 children	352	44	0.84	(0.54, 1.32)
Alcohol use				
Never (Ref)	709	131	Ref	---
Ever	880	119	0.74	0.56, 0.98
Smoking history				
Never (Ref)	921	163	Ref	---
≤ 10	251	39	0.86	0.59, 1.27
11 to 19	147	22	0.93	0.57, 1.51
≥ 20	531	68	0.80	0.59, 1.09
Hormone replacement therapy (postmenopausal only)				
Never (Ref)	314	55	Ref	---
Ever	943	114	0.66	0.46, 0.94
Oral contraceptive use				
Never (Ref)	647	110	Ref	---
Ever	1160	172	0.73	0.55, 0.96
BMI (kg/m ²) ^c				
< 25 (Ref)	785	134	Ref	---
25 to 29	563	79	0.92	0.67, 1.24
≥ 30	500	77	1.03	0.75, 1.41
BMI (kg/m ²) among premenopausal ^b				
< 25 (Ref)	223	50	Ref	---
25 to 29	99	21	1.11	0.62, 2.00
≥ 30	81	24	1.68	0.92, 3.07
BMI (kg/m ²) among postmenopausal ^b				
< 25 (Ref)	480	67	Ref	---
25 to 29	422	52	0.90	0.61, 1.33
≥ 30	372	50	0.99	0.66, 1.47

^a Adjusted for age at diagnosis, race/ethnicity, and Pathways/LACE study origin except in models with age at diagnosis or race/ethnicity as main predictors.

^b *P* for interaction not statistically significant (*P* > 0.05) in any tumor subtype model.

^c BMI = body mass index one year pre-diagnosis (LACE) and around diagnosis (Pathways).

CI = confidence interval; OR = odds ratio.

BMI while in the Pathways Study the opposite trend was observed, although these effect measures were not statistically significant.

For the subgroup analyses, among non-breastfeeding cases, parity of at least three children was associated with a statistically significant increased likelihood of having a triple-negative tumor (OR = 1.68; 95% CI = 1.00 to 2.81) and a Her2-overexpressing tumor (OR = 3.03; 95% CI = 1.27 to 7.23) compared with luminal A. In contrast, no differential associations of

breastfeeding and parity were observed among luminal B cases. All *P* values for interaction of parity by breastfeeding were not statistically significant. As for the effect of BMI by menopausal status, premenopausal triple-negative and Her2-overexpressing cases were more likely to be overweight (triple negative: OR = 1.82, 95% CI = 1.03 to 3.24; Her2-overexpressing: OR = 2.15, 95% CI = 0.70 to 6.58) or obese (triple negative: OR = 1.97, 95% CI = 1.03 to 3.77; Her2-overexpressing: OR = 2.51, 95% CI = 0.74 to 8.51) at diagnosis, yet the effect measures for Her2-overexpressing tumors were not

Table 4**Case-only odds ratios and 95% confidence intervals from logistic regression models^a of associations between breast cancer tumor subtypes and demographic, reproductive, and lifestyle risk factors, combined LACE and Pathways Studies (n = 2544)**

	Luminal A (comparison)		Triple negative ^a		HER2-overexpressing ^a		
	n	n	OR	95% CI	n	OR	95% CI
Age at diagnosis (years)							
≥ 65 (Ref)	637	68	Ref	---	23	Ref	---
50 to 64	871	115	1.99	0.85, 1.62	45	1.39	0.83, 2.32
< 50	355	105	2.78	1.99, 3.90	25	1.75	0.97, 3.15
Test for trend				$P \leq 0.0001$			$P = 0.03$
Race/ethnicity							
White (Ref)	1464	204	Ref	---	60	Ref	---
African American	92	44	3.14	2.12, 4.66	5	1.25	0.49, 3.21
Hispanic	135	21	0.93	0.57, 1.53	13	2.19	1.16, 4.13
Asian	135	12	0.53	0.28, 0.97	12	2.02	1.05, 3.88
Other	37	7	1.28	0.56, 2.94	3	1.95	0.58, 6.52
Menopausal status							
Postmenopausal (Ref)	1283	163	Ref	---	57	Ref	---
Premenopausal	406	91	0.84	0.55, 1.27	21	0.65	0.31, 1.33
Family history							
No (Ref)	1453	229	Ref	---	80	Ref	---
Yes	410	59	0.95	0.69, 1.29	13	0.62	0.34, 1.13
Age at first full-term pregnancy (years)							
Nulliparous (Ref)	335	52	Ref	---	13	Ref	---
< 26	959	163	1.28	0.90, 1.82	61	2.02	1.07, 3.80
≥ 26	567	72	0.93	0.63, 1.38	18	0.86	0.42, 1.79
Parity							
Nulliparous (Ref)	335	52	Ref	---	13	Ref	---
1 to 2 children	837	137	1.11	0.78, 1.58	40	1.30	0.68, 2.47
≥ 3 children	691	99	1.18	0.81, 1.72	40	1.82	0.94, 3.53
Lifetime duration of breastfeeding							
Never (Ref)	871	148	Ref	---	43	Ref	---
0 to 3 months	255	41	1.04	0.71, 1.52	16	1.29	0.71, 2.35
≥ 4 months	711	97	0.78	0.59, 1.03	32	0.86	0.54, 1.38
Parity among never breastfed ^b							
Nulliparous (Ref)	321	50	Ref	---	12	Ref	---
1 to 2 children	326	59	1.34	(0.87, 2.08)	15	1.52	(0.68, 3.41)
≥ 3 children	224	39	1.68	(1.00, 2.81)	16	3.03	(1.27, 7.23)
Parity among 0 to 3 months breastfed ^b							
1 to 2 children (Ref)	144	25	Ref	---	9	Ref	---
≥ 3 children	108	16	1.16	(0.53, 2.56)	7	1.82	(0.57, 5.80)
Parity among ≥ 4 months breastfed ^b							

Table 4 (Continued)**Case-only odds ratios and 95% confidence intervals from logistic regression models^a of associations between breast cancer tumor subtypes and demographic, reproductive, and lifestyle risk factors, combined LACE and Pathways Studies (n = 2544)**

1 to 2 children (Ref)	358	52	Ref	---	14	Ref	---
≥ 3 children	352	44	0.99	(0.63, 1.55)	17	1.23	(0.57, 2.66)
Alcohol use							
Never (Ref)	709	110	Ref	---	39	Ref	---
Ever	880	129	0.98	0.73, 1.30	40	0.94	0.59, 1.50
Smoking history							
Never (Ref)	921	146	Ref	---	51	Ref	---
≤ 10	251	41	0.95	0.65, 1.40	7	0.51	0.23, 1.14
11 to 19	147	21	0.89	0.54, 1.47	8	1.17	0.54, 2.56
≥ 20	531	78	0.98	0.72, 1.34	26	1.05	0.63, 1.73
Hormone replacement therapy (postmenopausal only)							
Never (Ref)	314	50	Ref	---	24	Ref	---
Ever	943	112	0.83	0.57, 1.20	33	0.45	0.26, 0.79
Oral contraceptive use							
Never (Ref)	647	80	Ref	---	29	Ref	---
Ever	1160	202	0.97	0.72, 1.31	63	1.12	0.69, 1.83
BMI (kg/m ²) ^c							
< 25 (Ref)	785	110	Ref	---	39	Ref	---
25 to 29	563	99	1.33	0.98, 1.81	31	1.21	0.74, 1.99
≥ 30	500	77	1.04	0.75, 1.45	23	1.03	0.59, 1.78
BMI (kg/m ²) among premenopausal ^b							
< 25 (Ref)	223	39	Ref	---	7	Ref	---
25 to 29	99	28	1.82	1.03, 3.24	7	2.15	0.70, 6.58
≥ 30	81	23	1.97	1.03, 3.77	7	2.51	0.74, 8.51
BMI (kg/m ²) among postmenopausal ^b							
< 25 (Ref)	480	59	Ref	---	25	Ref	---
25 to 29	422	60	1.08	0.73, 1.59	18	0.86	0.46, 1.61
≥ 30	372	43	0.76	0.49, 1.17	14	0.76	0.38, 1.51

^a Adjusted for age at diagnosis, race/ethnicity, and Pathways/LACE study origin except in models with age at diagnosis or race/ethnicity as main predictors.

^b *P* for interaction not statistically significant (*P* > 0.05) in any tumor subtype model.

^c BMI, body mass index one year pre-diagnosis (LACE) and around diagnosis (Pathways).

CI = confidence interval; HER2 = human epidermal growth receptor 2; OR = odds ratio.

statistically significant. Among luminal A cases, these associations were not observed. All *P* values for interaction of BMI by menopausal status were not statistically significant.

Discussion

In a pooled analysis of 2544 breast cancer cases using data from two prospective cohort studies housed within a large health maintenance organization, associations between breast cancer subtypes and various demographic, reproductive, and lifestyle factors were examined. In case-case analyses with the

luminal A cases as the reference group, luminal B cases were more likely to be younger at diagnosis and were less likely to consume alcohol, use HRT, and OCs. Triple-negative cases tended to be younger at diagnosis and African American, and were more likely to be overweight and/or obese at diagnosis if premenopausal. Women with triple-negative tumors were also less likely to breastfeed for longer periods, and were more likely to not breastfeed if they had at least three children. Her2-overexpressing cases were more likely to be younger at diagnosis and Hispanic or Asian, and less likely to use HRT. We

also found that these cases were more likely to be women with at least three children and no history of breastfeeding. These case-case observations suggest that heterogeneity in associations with traditional breast cancer risk factors exists by tumor subtype.

Several studies have assessed risk factor profiles of tumor subtypes, including the Carolina Breast Cancer Study (CBCS; $n = 1424$ *in situ* and invasive cases) [22], the Polish Breast Cancer Study (PBCS; 804 invasive cases) [27], and a pooled study of two Washington State (WS) case-control studies ($n = 1023$ invasive cases) [42,43] [see Additional data file 1]. The CBCS and PBCS were able to classify their triple-negative cases into basal-like and unclassified using CK5/6 and EGFR IHC expression data while the WS study did not do so. The CBCS performed case-case and case-control analyses while the PBCS and WS study conducted case-control analyses only. Although we were unable to further classify triple-negative cases into basal-like and unclassified, similar to the results of the CBCS (case-case analysis) and PBCS (case-control analysis) for basal-like cases, our triple-negative cases were more likely to be younger at diagnosis and African American. We also observed that premenopausal triple-negative cases tended to have higher BMI, which was in agreement with the basal-like cases in the CBCS but not the PBCS, the latter of which found no association. Interestingly, the WS study (case-control analysis) reported a suggestive increased risk of triple-negative tumors with increasing BMI among women currently using hormone therapy [42], yet we did not see any such association in our study. The WS study (case-control analysis) also reported that breastfeeding for at least six months was related to a reduced risk of triple-negative tumors [43]. Similarly, both the CBCS (case-case analysis) and our study found suggestive associations of shorter duration of breastfeeding (less than four months) with being more likely to have a triple-negative tumor. Furthermore, both studies observed a strong positive association for triple-negative cases (basal-like cases for CBCS) among women who had higher parity and never breastfed; the CBCS reported a case-only OR for parity of at least three children and no breastfeeding as 1.9 (95% CI = 1.1 to 3.4) compared with luminal A cases. The PBCS (case-control analysis) did not present data on the impact of breastfeeding on tumor subtypes.

As for luminal B and Her2-overexpressing cases, our results are in agreement with those of the CBCS that luminal B and Her2-overexpressing cases tended to be younger than luminal A cases. In contrast to the CBCS results, we observed that these cases were less likely to use HRT although luminal B cases were less likely to consume alcohol. No associations with these factors were observed in the PBCS, and the WS study did not examine luminal tumors separately by luminal A and luminal B subtype. We found that Her2-overexpressing cases were more likely to be Hispanic or Asian, but not African American, an observation which was not seen in any of the

other studies. In fact, the CBCS, comprised of only whites and African Americans, reported that Her2-overexpressing cases were slightly more likely to be African American. Finally, we observed that Her2-overexpressing cases were more likely to be women who had at least three children and had not breastfed, an association not seen in the CBCS.

Although our results tend to be in agreement with those of other studies, limitations of our study should be discussed. Only case-case comparisons were conducted, and it must be emphasized that the associations reported here are all in reference to risk of having a luminal A tumor subtype and should not be extended to risk of having invasive breast cancer. Case-case analyses among tumor subtypes are a useful exploratory tool to examine etiologic heterogeneity between the subtypes [53]. As previously mentioned, we have no data on CK5/6 and EGFR tumor markers to further classify triple-negative tumors into basal-like and unclassified. However, with additional funding, we plan to conduct these additional IHC assays in triple negative cases. Also, as there were a limited number of Her2-overexpressing tumors ($n = 94$; 3.7%), results concerning this subtype should be interpreted with caution. Finally, although our large study population of 2544 women diagnosed with invasive breast cancer was more ethnically diverse (76.6% white, 6.1% African American, 7.8% Hispanic, 7.4% Asian, 2.1% other) than other studies that have examined breast cancer risk factors among tumor subtypes, unlike the CBCS, we were unable to further examine risk factors by white and African American race/ethnicity due to limited numbers. Our findings, especially those regarding Hispanic and Asian differences, should be replicated in other population-based studies.

Conclusions

In summary, using a case-case analysis to assess the associations between traditional breast cancer risk factors and breast cancer subtypes (luminal A, luminal B, triple negative, and Her2-overexpressing), we observed significant heterogeneity of associations by tumor subtype. These varying associations by subtype lend further support to the growing evidence base that breast cancer is a heterogeneous disease defined by ER, PR, and Her2 expression with distinct etiologic pathways and prognoses. Future research should focus on refinement of tumor subtypes into more homogenous subgroups in order to best elucidate how risk factors may vary by subtype. Important modifiable factors that may be related to the development of specific tumor subtypes include obesity and possibly breastfeeding (triple negative) and alcohol consumption (luminal B), yet no clear modifiable risk factor profile was apparent for Her2-overexpressing subtypes due to a limited sample size. Given this information, public health programs aimed towards achieving a healthy weight and promoting breastfeeding might reduce the number of poor prognostic triple negative tumors among all breast cancer cases, especially the high-risk African American group.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MLK contributed to study conception and design, and acquisition, analysis, and interpretation of data; and drafted and revised the manuscript critically for important intellectual content. LHK and BJC contributed to study conception and design, and acquisition, analysis, and interpretation of data; and revised the manuscript critically for important intellectual content. EW contributed to analysis and interpretation of data; and revised the manuscript critically for important intellectual content. BM contributed to study conception and design; and revised the manuscript critically for important intellectual content. SEK contributed to analysis and interpretation of data; and revised the manuscript critically for important intellectual content. RSF contributed to acquisition of data; and revised the manuscript critically for important intellectual content. MML contributed to analysis and interpretation of data; and revised the manuscript critically for important intellectual content. CBA contributed to analysis and interpretation of data; and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Additional files

The following Additional files are available online:

Additional file 1

A word file containing a table that lists previous studies that have examined associations between common breast cancer risk factors and breast cancer tumor subtypes.

See <http://www.biomedcentral.com/content/supplementary/bcr2261-S1.doc>

Additional file 2

A word file containing a table that lists the distribution of demographic, reproductive, and lifestyle risk factors in the LACE and Pathways studies individually and combined (n = 2544).

See <http://www.biomedcentral.com/content/supplementary/bcr2261-S2.doc>

Additional file 3

A word file containing a table that lists case-only odds ratios and 95% confidence intervals from logistic regression models of associations between breast cancer tumor subtypes and demographic, reproductive, and lifestyle risk factors, LACE study (n = 1821).

See <http://www.biomedcentral.com/content/supplementary/bcr2261-S3.doc>

Additional file 4

A word file containing a table that shows case-only odds ratios and 95% confidence intervals from logistic regression models of associations between breast cancer tumor subtypes and demographic, reproductive, and lifestyle risk factors, Pathways study (n = 723). See <http://www.biomedcentral.com/content/supplementary/bcr2261-S4.doc>

Acknowledgements

The LACE Study was funded by the National Cancer Institute (R01 CA80027) and by the Utah Cancer Registry (N01 PC67000), with additional support from the State of Utah Department of Health. The Pathways Study was funded by the National Cancer Institute (R01 CA105274, R01 CA124924), the Department of Defense (BC043120), and the American Cancer Society (RSG-06-209-01-LR). We thank all LACE and Pathways Study participants, as well as the office and field staff. We acknowledge the technical assistance of Dr Xu Li of the KPNC Cytogenetics Laboratory and the programming assistance of Isaac Joshua Ergas at Kaiser Permanente, Division of Research. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the funding agencies.

References

1. American Cancer Society: **Cancer facts and figures 2008**. Atlanta: American Cancer Society; 2008.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: **Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study**. *JAMA* 2006, **295**:2492-2502.
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, Rijn M van de, Perou CM: **Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma**. *Clin Cancer Res* 2004, **10**:5367-5374.
4. Perou CM, Sorlie T, Eisen MB, Rijn M van de, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: **Molecular portraits of human breast tumours**. *Nature* 2000, **406**:747-752.
5. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, Blamey RW, Macmillan D, Ellis IO: **Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance**. *Eur J Cancer* 2006, **42**:3149-3156.
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M van de, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: **Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications**. *Proc Natl Acad Sci USA* 2001, **98**:10869-10874.
7. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D: **How basal are triple-negative breast cancers?** *Int J Cancer* 2008, **123**:236-240.
8. Bidard FC, Conforti R, Boulet T, Michiels S, Delaloye S, Andre F: **Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers**. *Ann Oncol* 2007, **18**:1285-1286.
9. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS: **Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients**. *Breast Cancer Res Treat* 2008, **111**:27-44.

10. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: **Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.** *Cancer* 2007, **109**:1721-1728.
11. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V: **The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999–2004.** *Cancer* 2008, **112**:737-747.
12. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: **The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.** *Clin Cancer Res* 2007, **13**:2329-2334.
13. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: **Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.** *Clin Cancer Res* 2008, **14**:1368-1376.
14. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: **Triple-negative breast cancer: clinical features and patterns of recurrence.** *Clin Cancer Res* 2007, **13**:4429-4434.
15. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L: **Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.** *Breast Cancer Res* 2006, **8**:R66.
16. Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezgebe HM, Makambi KH, Adams-Campbell L, Frederick WA: **Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.** *J Surg Res* 2007, **143**:109-118.
17. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW: **Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.** *Breast Cancer Res Treat* 2009, **113**:357-370.
18. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, Kinoshita T, Takei H, Takahashi K, Ikeda M, Nakashima K: **The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races.** *Breast* 2007, **16**(Suppl 2):S72-77.
19. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD: **Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.** *BMC Cancer* 2007, **7**:134.
20. Stark A, Kapke A, Schultz D, Brown R, Linden M, Raju U: **Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women.** *Breast Cancer Res Treat* 2008, **107**:405-414.
21. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL: **Early onset of breast cancer in a group of British black women.** *Br J Cancer* 2008, **98**:277-281.
22. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: **Epidemiology of basal-like breast cancer.** *Breast Cancer Res Treat* 2008, **109**:123-139.
23. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D: **Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.** *J Clin Oncol* 2006, **24**:5652-5657.
24. Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, Green VL, Brawley OW, Oprea-Lilies GM, Gabram SG: **High prevalence of triple-negative tumors in an urban cancer center.** *Cancer* 2008, **113**:608-615.
25. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP: **Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.** *Cancer* 2007, **110**:876-884.
26. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM: **Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.** *Mod Pathol* 2006, **19**:264-271.
27. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Garcia-Closas M: **Differences in risk factors for breast cancer molecular subtypes in a population-based study.** *Cancer Epidemiol Biomarkers Prev* 2007, **16**:439-443.
28. Parikh RR, Yang Q, Higgins SA, Haffty BG: **Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression.** *Int J Radiat Oncol Biol Phys* 2008, **70**:35-42.
29. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D: **Repeated observation of breast tumor subtypes in independent gene expression data sets.** *Proc Natl Acad Sci USA* 2003, **100**:8418-8423.
30. Brinton LA, Benichou J, Gammon MD, Brogan DR, Coates R, Schoenberg JB: **Ethnicity and variation in breast cancer incidence.** *Int J Cancer* 1997, **73**:349-355.
31. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R: **Ethnicity and breast cancer: factors influencing differences in incidence and outcome.** *J Natl Cancer Inst* 2005, **97**:439-448.
32. Hall IJ, Moorman PG, Millikan RC, Newman B: **Comparative analysis of breast cancer risk factors among African-American women and White women.** *Am J Epidemiol* 2005, **161**:40-51.
33. Mayberry RM, Stoddard-Wright C: **Breast cancer risk factors among black women and white women: similarities and differences.** *Am J Epidemiol* 1992, **136**:1445-1456.
34. Moorman PG, Millikan RC, Newman B: **Oral contraceptives and breast cancer among African-american women and white women.** *J Natl Med Assoc* 2001, **93**:329-334.
35. Palmer JR, Wise LA, Horton NJ, Adams-Campbell LL, Rosenberg L: **Dual effect of parity on breast cancer risk in African-American women.** *J Natl Cancer Inst* 2003, **95**:478-483.
36. Ursin G, Bernstein L, Wang Y, Lord SJ, Deapen D, Liff JM, Norman SA, Weiss LK, Daling JR, Marchbanks PA, Malone KE, Folger SG, McDonald JA, Burkman RT, Simon MS, Strom BL, Spirtas R: **Reproductive factors and risk of breast carcinoma in a study of white and African-American women.** *Cancer* 2004, **101**:353-362.
37. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE: **Risk factors for breast cancer according to estrogen and progesterone receptor status.** *J Natl Cancer Inst* 2004, **96**:218-228.
38. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: **Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status.** *Am J Epidemiol* 2000, **151**:703-714.
39. Lord SJ, Bernstein L, Johnson KA, Malone KE, McDonald JA, Marchbanks PA, Simon MS, Strom BL, Press MF, Folger SG, Burkman RT, Deapen D, Spirtas R, Ursin G: **Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case-control study.** *Cancer Epidemiol Biomarkers Prev* 2008, **17**:1723-1730.
40. Ma H, Bernstein L, Pike MC, Ursin G: **Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies.** *Breast Cancer Res* 2006, **8**:R43.
41. Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, Folsom AR: **Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there?** *Cancer Epidemiol Biomarkers Prev* 1995, **4**:319-326.
42. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI: **Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.** *Cancer Epidemiol Biomarkers Prev* 2008.
43. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI: **Reproductive and hormonal risk factors for postmenopausal luminal, HER2-overexpressing, and triple-negative breast cancer.** *Cancer* 2008, **113**:1521-1526.

44. Caan B, Sternfeld B, Gunderson E, Coates A, Quesenberry C, Slattery ML: **Life After Cancer Epidemiology (LACE) Study: a cohort of early stage breast cancer survivors (United States).** *Cancer Causes Control* 2005, **16**:545-556.
45. Kushi LH, Kwan ML, Lee MM, Ambrosone CB: **Lifestyle factors and survival in women with breast cancer.** *J Nutr* 2007, **137**:236S-242S.
46. Oehrli MD, Quesenberry CP, Leyden W: **2006 annual report on trends, incidence, and outcomes.** Kaiser Permanente, Northern California Cancer Registry; 2006.
47. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO: **High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.** *Int J Cancer* 2005, **116**:340-350.
48. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO: **Expression of luminal and basal cytokeratins in human breast carcinoma.** *J Pathol* 2004, **203**:661-671.
49. Brenton JD, Carey LA, Ahmed AA, Caldas C: **Molecular classification and molecular forecasting of breast cancer: ready for clinical application?** *J Clin Oncol* 2005, **23**:7350-7360.
50. Rijn M van de, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P: **Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.** *Am J Pathol* 2002, **161**:1991-1996.
51. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC: **Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.** *Breast Cancer Res* 2008, **10**:R67.
52. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pogram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology, College of American Pathologists: **American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.** *J Clin Oncol* 2007, **25**:118-145.
53. Begg CB, Zhang ZF: **Statistical analysis of molecular epidemiology studies employing case-series.** *Cancer Epidemiol Biomarkers Prev* 1994, **3**:173-175.